Compound class:
Synthetic organic
Comment: Compound 3 is reported as a thiazolidinedione analogue inhibitor of 15-hydroxyprostaglandin dehydrogenase (HPGD) [2]. This compound is also example 11 in patent US8637558 B2, which describes its use for the prevention or treatment of cardiovascular disease, gastrointestinal disease, renal disease and other conditions by increasing prostaglandin levels via inhibition of HPGD-induced prostaglandin metabolism [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Compound 3 significantly increases PGE2 levels in vitro, in A549 cells [2]. |
Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|